Analytical Data
-
Gene name
BRCA2
- Application
-
Alternative Names
FACD; FANCD1
-
Species
Human
-
Source
HEK293
-
Tag
Strep;His;Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51587
-
Expression Region
L2478-S3192
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BRCA2 protein, a crucial component in the maintenance of genomic stability, is part of the homology-directed repair (HDR) pathway crucial for the repair of double-strand breaks in DNA. Mutations in the BRCA2 gene are primarily linked to increased susceptibility to breast and ovarian cancers, making it a significant focus in cancer genetics. Research into BRCA2 has revealed its critical role in the recruitment and regulation of DNA repair machinery, specifically the RAD51 protein, which is vital for the repair process. Furthermore, understanding the structural and functional dynamics of BRCA2 protein interactions has illuminated its role in maintaining chromosomal integrity. Advances in techniques such as X-ray crystallography and cryo-electron microscopy have provided insights into the protein's multi-domain architecture and its mechanisms of action. The study of BRCA2 not only enhances our comprehension of hereditary cancer predisposition but also has profound implications for the development of targeted therapies and personalized medicine, particularly in the realm of PARP inhibitors, which exploit the synthetic lethality associated with BRCA2 deficiency. This ongoing research underscores the importance of BRCA2 in cancer biology and its potential as a therapeutic target, contributing to the broader understanding of genetic factors in cancer development and treatment.
